Stock Insights: Anadarko, Skullcandy, Polycom, Oncothyreon Mar. 6th

Anadarko Petroleum Corporation (NYSE:APC): UBS said Anadarko remains an attractive acquisition candidate and believes CEO Jim Hackett’s planned retirement in 2013 is a deadline for a potential takeout. Shares are Buy rated with a $105 price target.

Skullcandy Inc (NASDAQ:SKUL): Craig-Hallum said the CFO was brought on to facilitate the IPO process and to do acquisitions, which he did. The firm notes a search is on and that the newly appointed Chief Accounting Officer has been with the company for 4 years. Shares are Buy rated.

Polycom, Inc. (NASDAQ:PLCM): William Blair said it heard of at least two high-level departures in Polycom’s U.S. sales organization, including George Lillig, vice president of its U.S. government, education, and medical unit. The firm believes the timing of the departures is a negative indicator for Polycom’s Q1 sales performance in the U.S. Shares of Polycom are down 6% in early trading to $18.77.

Oncothyreon Inc (NASDAQ:ONTY): Cantor found this morning’s update from Merck KGaA (MKGAY) as expected since it believed Oncothyreon’s (NASDAQ:ONTY) Phase III cancer vaccine trial for Stimuvax would continue to its endpoint following the recommendation of an independent data and safety monitory board. Cantor has believed that the most likely outcome is for the trial to finish rather than stop early for either positive efficacy or futility. The firm reiterates a Buy rating on Oncothyreon shares with an $11 price target amid today’s heavy pullback.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at